# First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)

> First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) trades at $48.97 (+5.67%) as of 3:59:36 PM EST on Nov 4, 2026, +55.99% over the past month. Market cap is $1.95B, with 4.8 days to cover in short interest.

Canonical: https://massive.com/quote/trax
Data as of: 2026-11-04T20:59:36.070Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$48.97** +2.63 (+5.67%)
As of 3:59:36 PM EST on Nov 4, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +5.66% |
| 1W | +7.10% |
| 1M | +55.99% |
| YTD | +163.25% |
| 1Y | +163.25% |
| 52-wk range | $14.72 – $50.17 |

From daily closes through Nov 4, 2026.

## Key statistics

Today's trading snapshot for TRAX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $46.09 – $50.17 |
| Open | $48.01 |
| Prev close | $46.34 |
| Volume | 724.59K |
| Market cap | $1.95B |
| Shares out | 42.02M |

## Insider trading

[First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) insider trading](https://massive.com/quote/trax/insider-trading.md): open-market Form 4 buys and sells by First Tracks Biotherapeutics, Inc. Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events First Tracks Biotherapeutics, Inc. Ordinary Shares has disclosed to the SEC on Form 8-K.

- Nov 3, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 3, 2026, First Tracks Biotherapeutics, Inc. ("First Tracks") issued a press release announcing its financial results for the three and nine months ended September 30, 2026.”
- Oct 20, 2026 · Private placement
  “On October 19, 2026 (the "Closing Date"), First Tracks Biotherapeutics, Inc. ... closed its previously announced private placement ... of an aggregate 6,106,870 shares ... of the Company's common stock.”
- Oct 13, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On October 12 2026, the Company issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in Celiac Disease.”
- Jun 22, 2026 · Lease agreement
  “On June 15, 2026, First Tracks Biotherapeutics, Inc. (the "Company"), entered into a Sublease Agreement (the "Sublease") with AnaptysBio, Inc., a Delaware corporation ("AnaptysBio"), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121. The term of the Sublease commenced on June 15, 2026, and continues for a period of twelve (12) months from commencement.”
- Apr 20, 2026 · Acquisition consideration shares
  “On the Distribution Date, in connection with the Spin-Off, the Company issued 29,100,802 shares of Common Stock to AnaptysBio in consideration for the transfer of certain entities that are part of AnaptysBio's biopharma business. After this issuance, AnaptysBio held 29,100,902 shares of Common Stock.”

## TRAX short interest

How heavily TRAX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.8 |
| Short interest | 6.96M |
| Avg volume | 1.46M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## About First Tracks Biotherapeutics, Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Listed | Apr 6, 2026 |

## FAQ

### What is the First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) stock price today?

First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is trading at $48.97 (+5.67% on the day) as of 3:59:36 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is First Tracks Biotherapeutics, Inc. Ordinary Shares?

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a…

### What is the short interest in TRAX?

As of Oct 15, 2026, TRAX has 6.96M shares short and 4.8 days to cover.

### What exchange is TRAX listed on?

First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time TRAX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=TRAX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) insider trading](https://massive.com/quote/trax/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms